![]() |
市場調查報告書
商品編碼
1373349
照護端凝血測試產品市場規模 - 按測試類型(凝血酶原時間測試產品、活化凝血時間 (ACT/APTT) 測試產品)、按產品類型 - 全球預測,2023-2032 年Point of Care Coagulation Testing Products Market Size - By Test Type (Prothrombin Time Testing Products, Activated Clotting Time (ACT/APTT) Testing Products), By Product Type- Global Forecast, 2023-2032 |
2023 年至 2032 年間,全球照護端凝血測試產品市場的年複合成長率將達到 7.2%。由於領先公司不斷推動的合約和合作夥伴關係,該市場正在經歷需求。例如,2023 年 8 月,HemoSonics (R) 是一家專門從事治療急性出血的醫療技術的公司,從 Vizient, Inc. 獲得了其 Quantra 止血系統的創新技術合約。 Quantra (R) 止血系統包括配備 QPlus (R) 和 QStat (R) 盒的 Quantra 止血分析儀,只需 15 分鐘即可在照護端提供全面的全血凝固分析。 Quantra 已獲得 FDA 許可,可在各種臨床環境中使用,例如手術室、重症監護室和醫院實驗室,且維護、操作和解釋的資源要求極低。
這些合作有助於開發創新產品並擴大市場範圍。透過策略聯盟,公司增強了自身能力,從而推出了先進的凝血測試解決方案。因此,在追求尖端技術的推動下,照護端凝血和檢測產品的市場需求正在上升。
整個照護端凝血測試產品產業根據測試類型、產品類型和地區進行分類。
2023 年至 2032 年,活化凝血時間測試產品領域將經歷強勁成長。這些產品在即時監測凝血方面發揮著至關重要的作用,對於手術、重症監護和管理抗凝血治療至關重要。隨著醫療保健提供者尋求有效的解決方案來改善患者的治療結果並確保及時的臨床決策,對快速、準確結果的需求正在推動照護端凝血檢測產品行業的發展。
從 2023 年到 2032 年,消耗品部門將實現顯著的年複合成長率。這些基本組件,包括測試盒和試劑,對於在照護端進行凝血測試至關重要。該市場的成長歸因於對有助於快速凝血分析的可靠、易於使用的耗材的需求不斷增加。醫療保健專業人員依靠這些產品快速提供準確的結果,因此支持他們對照護端凝血測試產品市場前景的貢獻。
亞太地區照護端凝血檢測產品產業從2023 年到2032 年將呈現顯著的年複合成長率。這種激增可歸因於人們對凝血檢測重要性的認知不斷增強、醫療保健基礎設施的改善以及凝血障礙盛行率的上升。
對高效、便捷的凝血監測的需求推動了對這些產品的需求,最終改善整個亞太醫療保健系統的患者護理和臨床結果。此外,領先的地區公司推出的即時檢測產品創新數量不斷增加也為市場提供了支援。例如,2023 年 1 月,總部位於孟買的製藥公司 Cipla 推出了尖端的即時偵測設備 Cippoint。這種先進的設備提供了一系列全面的多種測試參數,包括凝血標記等。
Global Point of Care Coagulation Testing Products Market will witness 7.2% CAGR between 2023 and 2032. The market is experiencing demand due to the constant contracts and partnerships driven by leading companies. For instance, in August 2023, HemoSonics®, a company specializing in medical technology for managing acute bleeding, secured an Innovative Technology contract from Vizient, Inc. for its Quantra Hemostasis System. The Quantra® Hemostasis System includes the Quantra Hemostasis Analyzer equipped with QPlus® and QStat® Cartridges, delivering a comprehensive whole-blood coagulation analysis at the point of care in just 15 minutes. Quantra has received FDA clearance for usage in various clinical settings, such as operating rooms, intensive care units, and hospital laboratories, with minimal resource requirements for maintenance, operation, and interpretation.
These collaborations enable the development of innovative products and expand market reach. Through strategic alliances, companies enhance their capabilities, leading to the introduction of advanced coagulation testing solutions. As a result, the point of care coagulation and testing products market demand is on the rise, driven by the pursuit of cutting-edge technology.
The overall Point of Care Coagulation Testing Products Industry is classified based on test type, product type, and region.
Activated clotting time testing products segment will experience robust growth from 2023 to 2032. These products play a vital role in monitoring blood coagulation in real time, essential for surgeries, critical care, and managing anticoagulant therapies. The need for rapid and accurate results is driving the point of care coagulation testing products industry as healthcare providers seek efficient solutions to improve patient outcomes and ensure timely clinical decisions.
Consumables segment will register a notable CAGR from 2023 to 2032. These essential components, including test cartridges and reagents, are pivotal in conducting coagulation tests at the point of care. The market's growth is attributed to the increasing need for reliable, easy-to-use consumables that facilitate rapid coagulation analysis. Healthcare professionals rely on these products to deliver accurate results swiftly, therefore, supporting their contribution to the point of care coagulation testing products market outlook.
Asia Pacific point of care coagulation testing products industry will showcase a noteworthy CAGR from 2023 to 2032. This surge can be attributed to the growing awareness of the importance of coagulation testing, improved healthcare infrastructure, and a rising prevalence of coagulation disorders.
The demand for these products is driven by the need for efficient and accessible coagulation monitoring, ultimately enhancing patient care and clinical outcomes across Asia-Pacific healthcare systems. Additionally, the rising number of innovations in point of care testing product launches by leading regional companies also support the market. For instance, in January 2023, Cipla, a pharmaceutical company headquartered in Mumbai, unveiled Cippoint, a cutting-edge point-of-care testing device. This advanced device provides a comprehensive array of several testing parameters, including coagulation markers, among others.